This trial will compare the effect of a new drug, AZD9977, when used with dapagliflozin, to dapagliflozin used alone, in people with heart failure and chronic kidney disease. The trial will also look at different doses of AZD9977 to see what effect it has.
- Chronic Kidney Disease
- Heart Failure
1 Primary · 1 Secondary · Reporting Duration: Baseline (Day 1) until Week 12 (Day 85)
Awards & Highlights
6 Treatment Groups
AZD9977 Dose C
1 of 6
AZD9977 Dose B + dapagliflozin 10 mg
1 of 6
Dapagliflozin 10 mg
1 of 6
AZD9977 Dose A + dapagliflozin 10 mg
1 of 6
AZD9977 Dose C + dapagliflozin 10 mg
1 of 6
1 of 6
147 Total Participants · 6 Treatment Groups
Primary Treatment: Dapagliflozin · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 21 - 130 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Who else is applying?
What state do they live in?
How old are they?
|18 - 65||50.0%|
What site did they apply to?
What portion of applicants met pre-screening criteria?
|Did not meet criteria||66.7%|
Frequently Asked Questions
What is the current population enrolled in this research project?
"Affirmative. Clinicaltrials.gov indicates that this trial, first posted on January 26th 2021, is in the process of recruiting individuals to participate. Altogether, 500 patients must be found from 33 distinct sites for successful completion of the study." - Anonymous Online Contributor
Are there any vacant slots remaining in this trial for participants?
"Clinicaltrials.gov confirms that this clinical trial is in the process of recruiting participants, with a post date of January 26th 2021 and an edit on November 22nd 2022." - Anonymous Online Contributor
Has Dapagliflozin been explored by other researchers in the past?
"The University of Texas Health Science Center at San Antonio initially conducted research on dapagliflozin in 2014. Presently, there are 18460 completed trials and 63 active ones taking place primarily around Poughkeepsie, New York." - Anonymous Online Contributor
Is this a pioneering endeavor in its respective field?
"As of today, Dapagliflozin is a N/A approved drug after its first clinical trial in 2014. Sponsored by AstraZeneca and involving 700 individuals, it has since been studied extensively with 63 active trials conducted across 235 cities and 50 nations." - Anonymous Online Contributor
Is this research enrolled individuals of advanced age?
"The requirements for this study indicate that suitable candidates must be aged between 21 and 130. Additionally, there are 68 studies available to those under 18 while 1191 exist specifically tailored towards participants above 65 years of age." - Anonymous Online Contributor
Is enrollment currently open to join this research trial?
"Admission to this study requires individuals of ages between 21 and 130 years old that are suffering from cardiac failure. Aspiring participants must be cognizant that 500 spots are available in total." - Anonymous Online Contributor
What ailments does Dapagliflozin typically ameliorate?
"Dapagliflozin is frequently prescribed to treat pharmaceutical preparations, but it can also provide benefits for patients with diet-related issues, an exercise regimen that does not yield the desired results, and those who do not respond well to single therapy." - Anonymous Online Contributor
Does Dapagliflozin exhibit any potentially dangerous side effects?
"While the efficacy of Dapagliflozin is still uncertain, clinical data does suggest safety, so our team at Power gave it a score of 2." - Anonymous Online Contributor
How many health facilities are currently administering this trial in the state?
"At present, 33 medical centres are actively recruiting for this clinical trial. Prospective patients can select from a variety of locations including Poughkeepsie, New Bern and Augusta - to name but a few. It is important to choose the closest site in order to decrease travel requirements if you decide to partake in the study." - Anonymous Online Contributor